Stay updated on CAR-T Therapy for Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the CAR-T Therapy for Multiple Myeloma Clinical Trial page.

Latest updates to the CAR-T Therapy for Multiple Myeloma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedLocations section was expanded to list study sites across Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, Nebraska, New York, North Carolina, Pennsylvania, Tennessee, and Wisconsin. A Revision: v3.3.3 tag was added.SummaryDifference1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedAdded related topics 'Multiple myeloma' and 'MedlinePlus Genetics' and updated the page revision from v3.3.1 to v3.3.2.SummaryDifference0.2%

- Check45 days agoChange DetectedPublication note updated to indicate that PubMed entries are automatically filled and may not all pertain to the study. The page revision tag was updated to Revision: v3.3.1.SummaryDifference0.1%

- Check53 days agoChange DetectedNon-significant deletions remove a government funding notice and related topic links from the study record page. Core study information, such as title, conditions, and locations, remains unchanged.SummaryDifference0.4%

- Check67 days agoChange DetectedUpdates are limited to administrative timestamps and QC statuses (e.g., last update posted 2025-07-30) with no changes to core trial content such as eligibility criteria, endpoints, or locations—To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check74 days agoChange DetectedAdded related topics tags: Multiple myeloma and MedlinePlus Genetics. Core study details and eligibility criteria remain unchanged.SummaryDifference0.1%

Stay in the know with updates to CAR-T Therapy for Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CAR-T Therapy for Multiple Myeloma Clinical Trial page.